Tarsus Just Bet $800 Million on a Disease With Zero Treatments
Tarsus Pharmaceuticals is spending up to $800 million to acquire Alkeus and its late-stage Stargardt disease therapy, a rare eye condition with zero approved treatments. It's a bold bet on rare disease pricing in a market where nobody has planted a flag yet.
Imagine slowly going blind as a teenager, and your doctor telling you there's nothing they can do. That's the reality for roughly 30,000 Americans living with Stargardt disease, the most common inherited macular dystrophy in children. There is no approved treatment. Not one.
Tarsus Pharmaceuticals just wrote a check to change that.
The Eye-Care Company That Wants More
Tarsus announced it will acquire Alkeus Pharmaceuticals for up to $800 million, adding a late-stage oral therapy for Stargardt disease to its ophthalmology portfolio. The deal breaks down to about $450 million upfront (split between $270 million in cash and $180 million in Tarsus stock) plus up to $350 million in milestone payments tied to regulatory approval and first commercial sale.
If you're thinking "that's a lot of money for a drug that isn't approved yet," you're not wrong. But Tarsus isn't exactly strapped for cash. Its flagship product, XDEMVY (the first and only FDA-approved treatment for Demodex blepharitis, a common eyelid condition), has been printing money. In the second quarter of 2026 alone, XDEMVY brought in $173.9 million in net sales. The company just raised its full-year guidance to $685–705 million. Gross margins are sitting at a ridiculous 93%.
Tarsus sees itself as more than a one-product company, and this deal is the clearest signal yet.
What Alkeus Actually Has
The crown jewel here is gildeuretinol (also known as ALK-001), an oral drug designed to treat Stargardt disease at its biochemical root.
Here's what happens in Stargardt disease: a faulty gene called ABCA4 causes toxic vitamin A byproducts to pile up in the retina. Think of it like a clogged drain. The waste keeps building, damaging retinal cells, and vision gradually deteriorates. Most patients start losing sight in childhood or adolescence.
Gildeuretinol is a modified form of vitamin A that produces fewer of those toxic byproducts in the first place. It's less "fix the drain" and more "stop putting grease down it." The clever part: it does this without messing up the visual cycle, which means patients in studies haven't reported problems with night vision or color perception.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The clinical data, while early, paints a compelling picture. In one Phase 2 study (called TEASE-1), patients on gildeuretinol showed 21.6% slower growth of atrophic retinal lesions over two years compared to untreated patients. Interim results from another trial, TEASE-3, suggested the therapy could stall disease progression entirely in early-stage patients, with some remaining asymptomatic for up to six years.
Alkeus is now running NORTHSTAR, a pivotal Phase 3 trial that will determine whether this drug makes it to the FDA's desk.
The Billion-Dollar Bet on a Tiny Patient Population
This is where things get interesting. Stargardt disease affects roughly 10 to 12.5 people per 100,000 in the U.S. That's small. So how does Tarsus justify an $800 million price tag?
Two words: rare disease pricing.
Look at the precedent. Luxturna, Spark Therapeutics' gene therapy for a different inherited retinal condition, costs over $850,000 per treatment. Tepezza, used for thyroid eye disease, runs roughly $343,000 to $386,000 per course. When you're the only game in town for a devastating condition, payers tend to open their wallets.
Tarsus management has called Stargardt disease a "billion-dollar-plus opportunity" based on their own market research and physician surveys. Multiple outside estimates suggest the market is significant and growing, but nobody has planted a flag in it yet.
The deal structure also protects Tarsus from overpaying. Of the total $800 million headline, $250 million is contingent on U.S. regulatory approval, and another $100 million hinges on first commercial sale. If gildeuretinol never crosses the finish line, Tarsus limits its losses to the $450 million upfront.
Wall Street's Verdict: Cautiously Optimistic
Investors didn't exactly throw a parade, but they didn't panic either. Tarsus shares ticked up about 2% in early trading after the announcement, helped by a strong Q2 earnings beat on the same day.
Mizuho lowered its price target to $98 from $100, keeping an Outperform rating. That gap between the target and the stock's recent trading level suggests the Street thinks Tarsus has room to run, with or without Alkeus.
One reassuring detail: Tarsus also closed an oversubscribed $125 million PIPE (a private investment round) alongside the deal, backed by existing shareholders and investors connected to Alkeus. When the people closest to the asset are putting their own money behind the transaction, that's a meaningful vote of confidence.
The Bigger Picture: Eye Care M&A Is Heating Up
Tarsus isn't acting in a vacuum. The ophthalmology deal market has been on fire in 2025 and 2026. Biogen scooped up Apellis (maker of SYFOVRE for geographic atrophy) in a multibillion-dollar deal. ANI Pharmaceuticals grabbed Alimera Sciences at a 75% premium to its prior stock price. Roche has been signaling interest in retina-focused gene and cell therapies.
The pattern is clear: rare retinal diseases sit at the intersection of high unmet need and premium pricing, and bigger companies are willing to pay up for assets in the space. Retinal disorders represent the largest segment in ophthalmology, and gene/cell therapy is the fastest-growing drug category through 2035.
Tarsus is essentially making a land-grab play. XDEMVY gives it a commercial engine and ophthalmology credibility. Gildeuretinol, if it works, gives it a rare disease franchise with potentially massive per-patient economics.
What Could Go Wrong
Plenty. Gildeuretinol still needs to clear Phase 3 and earn FDA approval. Slowing lesion growth by 21.6% is encouraging, but regulators will want robust data from NORTHSTAR before giving the green light. The Stargardt patient population is small, which makes trials harder to enroll and results harder to power statistically.
There's also the question of competition. Gene therapy approaches targeting ABCA4 directly are in clinical development, and if one of those works, the market dynamics could shift quickly.
But for now, Tarsus has positioned itself as the frontrunner in a race where nobody else has crossed the starting line with a late-stage asset. For 30,000 Americans losing their sight with no options, that matters more than the deal math.
Deals & M&A
5 min read
Pathos AI Just Spent $2.2 Billion to Prove It's Not Just Another AI Hype Machine
Pathos AI dropped $125 million upfront and committed to a deal worth up to $2.2 billion for a Chinese cancer drug, then inked a partnership with AstraZeneca in the same week. It's the biggest test yet of whether AI can actually pick winners in drug development.
